BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19346026)

  • 1. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report.
    Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A
    Lung Cancer; 2009 Aug; 65(2):251-3. PubMed ID: 19346026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed-induced typhlitis in non-small cell lung cancer.
    Shvartsbeyn M; Edelman MJ
    J Thorac Oncol; 2008 Oct; 3(10):1188-90. PubMed ID: 18827618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed in first-line treatment of non-small cell lung cancer.
    Esteban E; Casillas M; Cassinello A
    Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
    Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
    Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
    Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
    Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.
    Barlési F; Tummino C; Tasei AM; Astoul P
    Lung Cancer; 2006 Dec; 54(3):423-5. PubMed ID: 17049669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed.
    Stavroulopoulos A; Nakopoulou L; Xydakis AM; Aresti V; Nikolakopoulou A; Klouvas G
    Ren Fail; 2010; 32(8):1000-4. PubMed ID: 20722569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed-induced pneumonitis: a case report.
    Loriot Y; Ferte C; Gomez-Roca C; Moldovan C; Bahleda R; Wislez M; Cadranel J; Soria JC
    Clin Lung Cancer; 2009 Sep; 10(5):364-6. PubMed ID: 19808196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
    Maione P; Rossi A; Di Maio M; Gridelli C
    Lung Cancer; 2009 Oct; 66(1):8-14. PubMed ID: 19328587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed and maintenance therapy for non-small cell lung cancer.
    Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
    [No Abstract]   [Full Text] [Related]  

  • 14. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy for advanced stage non-small cell lung cancer.
    Fathi AT; Brahmer JR
    Semin Thorac Cardiovasc Surg; 2008; 20(3):210-6. PubMed ID: 19038730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
    Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
    Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed-induced lung toxicity: a case report.
    Breuer S; Nechushtan H
    Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):76-7. PubMed ID: 21924594
    [No Abstract]   [Full Text] [Related]  

  • 18. [Non-small cell lung cancer - from treatment of relapse to treatments for relapses].
    Souquet PJ
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S108-13. PubMed ID: 18235402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Painful generalized erythematous patches: a severe and unusual cutaneous reaction to pemetrexed.
    Vitiello M; Romanelli P; Kerdel FA
    J Am Acad Dermatol; 2011 Jul; 65(1):243-4. PubMed ID: 21679840
    [No Abstract]   [Full Text] [Related]  

  • 20. [Second-line treatment of advanced non-small-cell lung cancer: role of pemetrexed].
    Pérol M
    Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S14-7. PubMed ID: 16273004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.